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Abstract
Background:  Despite exciting new targeted therapeutics against non-Hodgkin's lymphoma
(NHL), chemotherapy remains a cornerstone of therapy. While purine nucleoside analogs have
significant activity in low grade NHL, the pyrimidine nucleoside analog gemcitabine has been less
extensively studied, but has important activity. Use of the anti-CD20 monoclonal antibody
rituximab in combination with chemotherapy for B-NHL is becoming prevalent in clinical practice,
but has not been extensively studied in pre-clinical models.
Methods: We have tested the activity of gemcitabine ± rituximab in vitro and in scid/human NHL
xenograft models. We used two t(14;18)+, CD20+ follicular B cell NHL cell lines, DoHH2 a
transformed NHL line and WSU-FSCCL isolated from pleural fluid of a patient with indolent NHL.
Results: Gemcitabine is cytotoxic to DoHH2 and WSU-FSCCL cells in vitro, and the IC50 is 2–3
fold lower in the presence of rituximab. Apoptosis is also enhanced in the presence of rituximab.
Clearance of NHL cells from ascites in scid mice is prolonged by the combination, as compared with
either agent alone. Most importantly, survival of scid mice bearing human NHL cells is significantly
prolonged by the combination of gemcitabine + rituximab.
Conclusion: Based on our pre-clinical data showing prolonged survival of mice bearing human
lymphoma cell line xenografts after treatment with gemcitabine + anti-CD20 antibody, this
combination, expected to have non-overlapping toxicity profiles, should be explored in clinical
trials.
Background
Non-Hodgkin's lymphoma (NHL) is increasing in inci-
dence and is now the fifth most common malignancy in
the U.S. Despite novel targeted biologic treatment
options, chemotherapy remains an important component
of therapy. Furthermore, most patients with indolent lym-
phoma and at least half of all patients with aggressive
NHL are not cured [1]. Improved therapeutic approaches
are needed.
Gemcitabine is a pyrimidine nucleoside analog with clin-
ical anti-cancer activity. Purine nucleoside analogs such as
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fludarabine, cladribine and pentostatin have been exten-
sively studied and have significant activity against certain
non-Hodgkin's lymphoma subtypes, particularly indolent
forms. Though less well studied, an increasing body of
data indicates activity of gemcitabine against lymphoma,
both Hodgkin's and NHL [2-7]. The precise place of gem-
citabine in the therapeutic armamentarium for NHL
remains to be elucidated.
The chimeric anti-CD20 monoclonal antibody rituximab
is active as a single agent in B cell NHL [8]. In addition, it
may sensitize cells to the action of chemotherapeutic and
other biologic agents pre-clinically [9-12], as well as in
patients [13,14]. While mechanisms of rituximab action
include direct apoptotic induction, complement activa-
tion and antibody dependent cytotoxicity, which of these
is important may depend on the experimental conditions,
and the relative importance in patients remains to be
determined (reviewed in [15]). The same mechanisms, as
well as intracellular signaling [16], may account for chem-
osensitization, but again the exact means by which this
occurs in patients remains to be fully elucidated. One pre-
vious report has demonstrated in vitro sensitization of
aggressive B cell NHL cell lines to gemcitabine by rituxi-
mab [10]. Here we extend these in vitro results to addi-
tional human CD20+ lymphoma cell lines that carry the
t(14:18) translocation, perhaps more analogous to the
clinical use of rituximab. More importantly, we demon-
strate that gemcitabine + rituximab enhances survival in
vivo  in a human B-NHL cell line/scid  mouse xenograft
model.
Methods
Cell culture and growth assay
Cells are incubated under standard conditions and cell
numbers are determined by methyl thiazol tetrazolium-
bromide (MTT) assay as before [17]. Briefly, DoHH2 [18],
a t(14;18)+ transformed lymphoma cell line, was
obtained from Deutsche Sammlung von Mikroorganis-
men und Zellkulturen GmbH (DMSZ, German Collection
of Microorganisms and Cell Cultures, Braunschweig, Ger-
many). WSU-FSCCL, as previously reported [19], was iso-
lated from pleural fluid of a patient with follicular grade I
lymphoma, contains t(14;18), is EBV negative and
behaves in scid  mice as a more indolent disease [17],
although it does contain a c-myc translocation.
Anti-CD20 monoclonal antibody
Chimeric anti-CD20 (clone C2B8, rituximab) obtained
from IDEC (San Diego, CA), and gemcitabine (generously
supplied by Lilly, Indianapolis, IN) were injected intra-
peritoneally (ip).
Apoptosis and cell cycle
Cell cycle was analyzed by DNA content per cell, by pro-
pidium iodide (PI) staining of nuclei from hypotonically
lysed cells [20]. Apoptosis was determined by dual stain-
ing of 1 × 105 intact cells in 100 µl calcium binding buffer
containing 5 µl of fluoroscein isothiocyanate (FITC)-
labeled annexin V (Pharmingen) and 5 µg/ml PI for 15
minutes in the dark, followed by analysis by flow cytom-
etry (FACScan).
Poly(ADP-ribose) polymerase (PARP) cleavage assay
DoHH2 and WSU-FSCCL cells were lysed in cold radioim-
munoprecipitation assay (RIPA) buffer [21] containing
100 µg phenylmethanesulfonyl fluoride (PMSF)/ml and 1
µg aprotinin/ml for 30 min on ice, pelleted and the super-
natant separated by 4–20% SDS-PAGE. Transfer was to
Immobilon-P, blocked with 1% casein-0.04% Tween-20
and probed with anti-PARP C2–10 antibody (Trevigen,
Gaithersburg, MD). Secondary antibody was horseradish
peroxidase labeled anti-mouse IgG (1:3000) for 30 min,
detected by chemiluminescence and Hyperfilm ECL
(Amersham, Piscataway, NJ). Densitometry utilized NIH
Image 1.61 software.
Scid/human xenograft
Female CB17 scid mice were bred, housed and treated in
the Fox Chase Cancer Center Laboratory Animal Facility
under an approved protocol. Mice 4–8 weeks old were
injected ip with either 1 × 107 WSU-FSCCL cells or 5 × 106
DoHH2 cells. Mice were observed daily and euthanized
when they appeared ill. Lymphoma involving diffuse ade-
nopathy, splenomegaly, infiltration of liver and bone
marrow, along with ascites developed in untreated mice
with each model, at 8–11 weeks with WSU-FSCCL and 4–
6 weeks with DoHH2. Cells were collected sequentially
from ascites by peritoneal washings and analyzed, or mice
were followed for survival. For ascites clearance, mice
bearing DoHH2 received 20 µg rituximab intraperito-
neally (ip) on day 3 after lymphoma cell injection and/or
gemcitabine 120 µg/gm ip on day 4, while mice bearing
WSU-FSCCL received 100 µg rituximab intraperitoneally
(ip) on day 7 after lymphoma cell injection, and/or gem-
citabine 120 µg/gm ip on day 8. For survival, mice bearing
DoHH2 received 5 µg rituximab on days 2, 9 and 16 and/
or gemcitabine 120 µg/gm ip on days 3, 10 and 17.
Results
Cell growth inhibition by gemcitabine and rituximab
Both DoHH2 and WSU-FSCCL cells are growth inhibited
by gemcitabine with an IC50 of 1 nM after 72 hr incuba-
tion (Figure 1). Addition of rituximab alone or in combi-
nation with gemcitabine had little effect on WSU-FSCCL
cells in vitro. In contrast, DoHH2 cells are growth inhib-
ited about 35% by 20 µg/ml rituximab. The maximal
rituximab effect is seen at 1 µg/ml. This is accord with dataBMC Cancer 2005, 5:103 http://www.biomedcentral.com/1471-2407/5/103
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that CD20 sites are saturated at this level, while effective
serum levels in patients are felt to be 25 µg/ml. Thus, there
is essentially no dose response at clinically achievable lev-
els. This precludes the calculation of synergy by the stand-
ard approach [22], as has been concluded by other
investigators as well [23]. Because of our prior experience
that oligonucleotides can interfere with drug and anti-
body uptake, we separated addition of the two agents by
4 hours to preclude direct physical interaction of the anti-
body and drug, however, no effect of order of addition
within 4 hours was observed with rituximab and gemcit-
abine (data not shown).
Cell cycle alteration by gemcitabine and rituximab
Continuous exposure to 2.5 nM gemcitabine led to accu-
mulation of DoHH2 cells in the S phase, as has been gen-
erally reported for gemcitabine [24]. WSU-FSCCL cells,
however, accumulated in the G2/M phase of the cell cycle
(Figure 2). Although rituximab alone had no significant
cell cycle effects on either cell line, nor on the S phase
accumulation of DoHH2 cells, the combination of gem-
citabine + rituximab led to S phase accumulation of WSU-
FSCCL cells. Statistical analysis of S phase block in WSU-
FSCCL cells comparing 2.5 nM gemcitabine alone versus
gemcitabine plus rituximab revealed p < 0.001. Thus, the
combination had different cell cycle effects on WSU-
FSCCL than did either agent alone. The precise basis of
this change is unclear, though presumably involves an
alteration in the S phase DNA damage sensor, which
appears to involve the ATM gene [25].
Apoptosis induced by gemcitabine and rituximab
Apoptosis was assayed by annexin V staining, which
detects the altered location of phosphatidyl serine to the
outer surface of the cell membrane. Apoptosis was
induced at modest levels by gemcitabine or rituximab, but
significantly more apoptosis was induced by the combina-
tion in both cell lines studied (Figure 3). When apoptosis
was separated into early apoptosis, in which cells still
exclude propidium iodide (PI), and late apoptosis where
cells are PI permeable, early apoptosis is induced by the
combination in DoHH2 cells, whereas both early and late
apoptosis are demonstrated in WSU-FSCCL cells.
Apoptosis was also assessed by cleavage of PARP, which
occurs when the apoptotic pathway is activated, eventu-
ally leading to cleavage of caspase 3 and of other
downstream proteins including PARP. In each cell line,
Cytotoxicity of rituximab and gemcitabine Figure 1
Cytotoxicity of rituximab and gemcitabine. WSU-FSCCL or DoHH2 cells incubated with varying concentrations of gemcitab-
ine, and 4 hr later ± 20 µg/ml rituximab. Cytotoxicity is expressed as percentage of untreated control cells at 72 hr.
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rituximab and gemcitabine result in PARP cleavage, with
additional cleavage using the combination (Fig 4).
In vivo efficacy of gemcitabine ± rituximab
We initially screen for efficacy of therapy in our model by
assessing the prevention of growth of cells in ascites fluid
[11,17]. The lymphomas grow as bulky mesenteric nodes
with development of hepatosplenomegaly, as well as dif-
fuse adenopathy elsewhere, but not with measurable dis-
ease. While ascites represents only a small part of the
animals' disease burden, it can be repeatedly sampled as
an indicator of overall tumor in a mouse. Given the
differing rates of growth of the cell lines in mice, treat-
ment was started on day 3 after DoHH2 cell injection and
day 7 after WSU-FSCCL cell injection. For DoHH2 (Figure
5A), gemcitabine delayed growth, so that at day 18 there
were fewer lymphoma cells in the ascites fluid, however,
by day 32 there was no longer a difference. Rituximab is
effective in this model, although cells do eventually reac-
cumulate in ascites. There is a trend to longer time to
recurrence of lymphoma cells with combined therapy. In
the WSU-FSCCL model (Figure 5B), while gemcitabine
alone had no effect, it did enhance the rituximab-medi-
ated delay in lymphoma cell re-growth.
The most important endpoint for treatment efficacy, since
there is not an externally measurable lesion, is survival of
mice bearing the human lymphoma cell lines. We have
performed duplicate experiments using mice injected with
DoHH2 cells (Figure 6). At the gemcitabine dose of 120
Effect of gemcitabine and rituximab on cell cycle Figure 2
Effect of gemcitabine and rituximab on cell cycle. Cells (0.25 × 106/ml) incubated ± 20 µg/ml rituximab for 4 hr, then ± 2.5 nM 
gemcitabine for 24 hr. Cells stained with propidium iodide, analyzed by flow and cell cycle parameters calculated (ModFit LT 
program). A typical flow result is also shown (Figure 2A).
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µg/gm (~ 2.4 mg/mouse), used in previous reports [26]
weekly for 3 doses, there was modest prolongation of
median survival, with 0/5 and 2/6 long-term survivors in
the two experiments. We used sub-maximally tolerated
doses of rituximab, 5 µg per mouse, which had modest
therapeutic effect (1/11 long-term survivors combined).
Combination therapy with these two agents at the same
dose and schedule, however, markedly prolonged survival
(p = 0.04, left; p = 0.01, right for rituximab + gemcitabine
vs rituximab), and cured 9 of 11 mice. The surviving mice
were euthanized at the end of the experiment and found
to be histologically negative for lymphoma.
Discussion
This report demonstrates the anti-lymphoma activity of
the pyrimidine analog gemcitabine in vitro and in a scid
mouse human lymphoma xenograft model. Rituximab is
an active therapy for CD20+ NHL as a single agent and in
combination with some biologic and chemotherapeutic
agents [9-12]. The generalizability and mechanism of
chemosensitization by rituximab has not been fully
explored. Evidence for several mechanisms of rituximab
mediated lymphoma cell death has been presented
including direct induction of apoptosis, complement
mediated killing and antibody-dependent cell mediated
cytotoxicity (ADCC). Much of the data addressing these
Apoptosis induced by gemcitabine and rituximab Figure 3
Apoptosis induced by gemcitabine and rituximab. Cells treated as in figure 2, except with 10 nM gemcitabine, then stained with 
annexin V and propidium iodide. Top left panel (A) is total annexin V positive cells. Top right  panel (B) shows early apoptosis 
(annexin+/PI-, left) and late apoptosis (annexin+/PI+, right). A typical dot plot (C) is also shown.
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processes comes from in vitro systems, and the relevance
to activity in patients remains uncertain. Our in vitro data
in this report rely only on direct apoptosis, as we do not
add human serum as a complement source nor effector
cells. Direct apoptosis can be affected by degree of
crosslinking of the antibody, which in turn can be control-
led by humoral or cell surface molecules. Complement
activity may be altered by inhibitory factors and may dif-
fer between human serum in vitro and mouse comple-
ment in murine models. We have found that crosslinking
does enhance the degree of apoptosis after rituximab
treatment in our two cell lines, while addition of comple-
ment has little effect (data not shown). ADCC depends on
effector cells, and even the precise effector cells remain
uncertain. Scid mice have residual granulocytes and NK
cells, and depletion of these cells can abolish rituximab
efficacy [27]. To understand the mechanisms of resistance
to rituximab will require more complete knowledge of
which of these mechanisms of action is or are most
important in patients [15]. Recent data suggests that
rituximab can alter intracellular signaling, even without
inducing apoptosis, in ways that can sensitize cells to
chemotherapy effects [16].
Our results demonstrate that the combination of gemcit-
abine and rituximab inhibits NHL cell growth, induces
apoptosis in these cells, and, most importantly, is effective
in prolonging survival of mice bearing human t(14;18)+
lymphoma cells. Prior reports have shown additive effects
of gemcitabine and rituximab in aggressive NHL cell lines
in vitro [10]. In that report, aggressive NHL cell lines that
were relatively resistant to both gemcitabine and rituxi-
mab were pre-treated with rituximab for 24 hours and
then treated with gemcitabine for 18 hours and found to
have modest increases in hypodiploid cells and PI positive
cells after PI staining.
The cell cycle changes seen after gemcitabine treatment
alone, and in combination with rituximab, are cell line
dependent. WSU-FSCCL cells, in contrast to most cells,
are not blocked in S phase by gemcitabine alone, but are
after rituximab is added. This may reflect altered
PARP cleavage induced by gemcitabine and rituximab Figure 4
PARP cleavage induced by gemcitabine and rituximab. Cells treated as in figure 2, but for 48 hr with either 2.5 or 5 nM gemcit-
abine, the cell lysates analyzed by Western using anti-PARP (C2–10, Trevigen, Inc), which detects both intact PARP (116 kD) 
and the apoptotic marker PARP cleavage fragment (85 kD), or G3PDH as a loading control.
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intracellular signaling that could restore a putative S phase
DNA damage sensor, such as the ATM pathway [25]. Sim-
ilarly, induction of early versus late apoptosis is also cell
line dependent. Further exploration of the biochemical
basis of these changes is warranted to better understand
which of the many potential targets of a pyrimidine nucl-
eoside analog are the important determinants of gemcit-
abine activity against NHL cells, and how these targets are
affected by rituximab.
Clearance of NHL cells from ascites by treatment with gemcitabine and rituximab Figure 5
Clearance of NHL cells from ascites by treatment with gemcitabine and rituximab. Scid mice were injected intraperitoneally (ip) 
with 5 × 106 DoHH2 cells (A, top) or 10 × 106 WSU-FSCCL cells (B, bottom). Mice received 20 µg rituximab (ip) on day 3 and 
120 µg gemcitabine/gm body weight (ip) on day 4 after injection of DoHH2 cells. Ascites was collected on day 18, 32 and 42. 
Untreated scid/DoHH2 mice died prior to day 42. Because of the slower development of lymphoma with WSU-FSCCL, mice 
were treated with 100 µg rituximab (ip) on day 7 and 120 µg gemcitabine/gm body weight (ip) on day 8 after injection of WSU-
FSCCL cells. Ascites was collected on days 22, 34 and 51. Cells from ascites were stained with PE anti-human CD45 antibody 
and analyzed by flow cytometry.
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Concurrent treatment of B cell lymphoproliferative disor-
ders (NHL and CLL) with rituximab and chemotherapy is
becoming more common, and data suggests benefit in
time to disease progression in indolent disease [14] and
also in overall survival in aggressive disease [13]. Ques-
tions remain regarding the optimal way to combine ritux-
imab and chemotherapy and whether therapeutic efficacy
of specific chemotherapeutic agents is enhanced by ritux-
imab. Pre-clinical studies of the interaction of chemother-
apy agents and rituximab may provide insight to guide the
development of appropriate clinical trials.
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